Project

Deconvolution of the polyclonal antibody response targeting HIV-1 allowed the identification of broadly neutralizing monoclonal antibodies (bNAbs) targeting the viral envelope. Infusion of bNAbs protects against HIV-1 acquisition and decreases viral load. bNAbs kill HIV-1-infected cells, modulate host immune responses, and, when associated to latency-reversal agents, delay viral rebound in animal models. These antiviral activities are mediated by the Fc region, which is required for optimal in vivo efficacy. Thus, the landscape of Fc effector functions triggered by bNAbs is under intense investigation. Our aim is to decipher the molecular mechanisms underlying the sensitivity of HIV-1-infected cells to Fc effector functions.